Advent Life Sciences GP LLP

Report and Accounts
For the period 1 March to 31 December 2019

Registered in England and Wales Number: OC426238

A975UQ4P
A14 23/06/2020 #2
COMPANIES HOUSE

Contents

Members' Report	2
Statement of Members' Responsibilities in Relation to the Accounts	.3
Profit and Loss Account	4
Balance Sheet	5
Notes to the Financial Statements	6

Annual Report and Financial Statements Company Registration Number: OC426238 Period 1 March to 31 December 2019

Members' Report

The Members' have pleasure in submitting their report and accounts for the period 1 March to 31 December 2019.

Activities

Advent Life Sciences GP LLP is General Partner to Advent Life Sciences Fund I LP, Advent Life Sciences Fund II LP and Advent Life Sciences II Co-invest LP ("the Funds"). The Funds are Limited Partnerships' registered in England and Wales, and are established for Investment purposes. Advent Life Sciences GP LLP was established on 1 March 2019. It has not traded in the period 1 March to 31 December 2019.

Members

The designated Members of the LLP during the period were as follows:

Advent Life Sciences LLP ALS III MemberCo Ltd

Auditors

Members have not required the company to obtain an audit in accordance with section 477 of the Companies Act 2006.

By order of the Members

M. S. A. Malik

On behalf of Advent Life Sciences LLP

22 June 2020

Company Registration Number: OC426238 Period 1 March to 31 December 2019

Statement of Members' Responsibilities in Respect of the Members' Report and the Financial Statements

The members are responsible for preparing the Members' Report and the financial statements in accordance with applicable law and regulations.

The Limited Liability Partnerships (Accounts and Audit) (Application of Companies Act 2006) Regulations 2008 require the members to prepare financial statements for each financial year. Under that law the members have elected to prepare the financial statements in accordance with UK Accounting Standards and applicable law (UK Generally Accepted Accounting Practice, including FRS 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland.*

Under Regulation 8 of the Limited Liability Partnerships (Accounts and Audit) (Application of Companies Act 2006) Regulations 2008 the members must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the LLP and of its profit or loss for that period. In preparing these financial statements, the members are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- assess the LLP's ability to continue as a going concern, disclosing, as applicable, matters related to going concern; and
- use the going concern basis of accounting unless they either intend to liquidate the LLP or to cease operations, or have no realistic alternative but to do so.

Under Regulation 6 of the Limited Liability Partnerships (Accounts and Audit) (Application of Companies Act 2006) Regulations 2008, the members are responsible for keeping adequate accounting records that are sufficient to show and explain the LLP's transactions and disclose with reasonable accuracy at any time the financial position of the LLP and enable them to ensure that its financial statements comply with those regulations. They are responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error, and have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of the LLP and to prevent and detect fraud and other irregularities.

Advent Life Sciences GP LLP

Annual Report and Financial Statements Company Registration Number: OC426238 Period 1 March to 31 December 2019

Profit and Loss Account

For the period 1 March to 31 December 2019

During the period 1 March to 31 December 2019 the company did not trade and received no income and incurred no expenditure. Consequently, during this period the company made neither a profit nor a loss.

Δ

Balance Sheet

As at 31 December 2019

	2019 £	
Current assets		
Amounts due from Members	2	
Net Assets attributable to Members	2	
Total Members' Interests	2	

For the period 1 March to 31 December 2019 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 (as applied by the Limited Liability Partnerships (Accounts and Audit) (Application of the Companies Act 2006) relating to small LLPs.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.

These accounts have been prepared in accordance with the provisions applicable to LLPs subject to the small LLPs regime.

These accounts were approved by the Board on 22 June 2020 and signed on their behalf by:

M. S. A. Malik

On behalf of Advent Life Sciences LLP

The notes on page 6 form part of these accounts.

Notes to the Financial Statements

1. Profit and loss account

During the period 1 March to 31 December 2019 the company did not trade and received no income and incurred no expenditure. Consequently, during the period the company made neither a profit nor a loss.

2. Accounting policy

The financial statements have been prepared in accordance with applicable accounting standards and under the historical cost accounting rules.

3. Reconciliation of Members' Interests

	2019 £
Opening Members' Interests	-
Members' Capital contributions	2
Closing Members' Interests	2

4. Related Party Transactions

The Company has claimed the exemption from disclosure of transactions with group companies in accordance with Financial Reporting Standard No. 8 'Related Party Transactions' on the grounds that 100% of voting rights are controlled within the group and that the parent company accounts are publicly available (please refer to Note 5 'Ultimate Parent Undertaking').

5. Ultimate parent undertaking

The company's ultimate parent undertaking is Advent Life Sciences LLP, a limited liability partnership registered in England and Wales. Copies of the consolidated accounts of Advent Life Sciences LLP may be inspected at Companies House.